WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 19, 1541-1581. Review Article ISSN 2277–7105

POLYSACCHARIDE-BASED DRUG DELIVERY SYSTEMS IN CANCER THERAPY: A COMPREHENSIVE REVIEW OF APPLICATIONS AND ADVANCES

Akash P. Patil*[1], Nikhil M. Yadav[2], Prasannjeet S. Bhopale[2], Chetan M. Patil[3], Pratiksha P. Patil[4] and Dhanashri V. Shinde[5]

[1]Department of Pharmaceutical Quality Assurance, Bharati Vidyapeeth Collage of Pharmacy, Kolhapur, Maharashtra, India.

[2]Department of Pharmaceutical Chemistry, Bharati Vidyapeeth Collage of Pharmacy, Kolhapur, Maharashtra, India.

[3]Department of Pharmaceutical Quality Assurance, Tatyasaheb Kore Collage of Pharmacy, Warananagar, Maharashtra, India.

[4]Yashwant Redekar Collage of Pharmacy, Nesari, Maharashta, India.

[5]Department of Pharmaceutical Quality Assurance, Vasantidevi Patil College of Pharmacy, Kodoli.

Article Received on
22 August 2024,

Revised on 12 Sept. 2024,
Accepted on 02 Oct. 2024

DOI: 10.20959/wjpr202419-34100

***Corresponding Author**
Akash P. Patil
Department of Pharmaceutical Quality Assurance, Bharati Vidyapeeth Collage of Pharmacy, Kolhapur, Maharashtra, India.

ABSTRACT

Tumor therapy is a growing research topic due to the increasing global frequency of tumor. Challenges include antitumour medicines' organisation lethality, lack of tumor localization, and diffusion throughout the entire body. Anti tumor drugs have short half-lives in circulation of blood and unsatisfactory cinacalcet characteristics. Amalgamation of low molecular mass pharmaceuticals to supermolecule transporters has been utilized to improve drug distribution. Various supermolecule, comprising proteins, antibodies, polysaccharides, lectins, and synthetic polymers, have been linked with antitumour medicines. tumor is defined by the unrestrained proliferation of aberrant cells, that can infect adjacent tissues and spread to other parts of the body via metastases. Currently, tumor cure techniques include surgery, radiation, and chemotherapy. Chemotherapy is required for organisation sic cure of metastases associated with tumour development. Organisations based on polysaccharides have received

increased interest due to their low cost, abundance, exceptional. Physicochemical and biological characteristics, along with the straightforwardness of the chemical reactions needed for particular modifications. Polysaccharides are useful as drug transporters due to their steadiness, non-lethality, and biodegradability.

KEYWORDS: Chitosan, PTX, Curcumin, Alginate, Pectin Cisplatin.

INTRODUCTION

Tumor therapy has become one of the most researched topics in recent years, owing to the increasing global frequency of tumor. The most significant hurdles to influence tumor therapy include anti tumor medicines' organisation sic lethality, lack of tumor localization, and diffusion all over the entire body, comprise tumor tissues. Furthermore, anti tumor drugs have short half-lives in circulation of blood and exhibit unsatisfactory cinacalcet characteristics, which are among the disadvantages of tumor cure. Amalgamation of low molecular mass pharmaceuticals to macromolecular transporters has been utilized to overcome this issue, which improves the distribution of drug molecules throughout the body. Various supermolecule, comprising proteins, antibodies, polysaccharides, lectins, and synthetic polymers, have been linked with anti-tumour medicines.[1]

Tumor is defined by the unrestrained gain of aberrant cells.[2,3] These malignant cells can infect adjacent tissues and spread to other parts of the body via the blood and lymphatic organisations (metastases).[4] Every year, more than 550,000 people die from tumor in the United States, accounting for one out of every four deaths.[5] Currently, tumor cure techniques include Surgery, radiation, and eradicator. Localized cures, such as surgery and irradiation therapies, are influence only when hostile cells are restricted to the cured area. Eradicator is thus required for the organisation siccure of metastases associated with tumor development at the local and regional levels.[6] Evolution are the results of death due to tumor.

The antitumour medications employed in Eradicator are comprehensive antiproliferative agents, which is the cause of splitting cells first. These anti tumour compounds include antimetabolites, alkylating agents, DNA-complexing agents, mitotic inhibitors, and hormones, and they work by interfering with some part of DNA replication, repair, translation, or cell division. They rely mostly on tumor cells' increased gain rate and are thus not fully selective for tumor cells. The prolonged use of chemotherapy causes deadly harm to

gain benign tumor cells, which is especially true in the cure of solid tumors, because the bulk of malignancy cells do not split fast.[7]

Studies have demonstrated that administering cytotoxins to patients with substantial tumor burdens leads to remissions of varying lengths and intensities, followed by the re-emergence and spread of more aggressive and multidrug-resistant tumor forms.[8] Despite decades of intensive research, the long-term prognosis for patients with aggressive tumor remains poor. There is a pressing need for innovative approaches to designing anti tumor drugs that have lower lethality and higher therapeutic indices.[9,10]

Polysaccharide-based organisations have garnered increased attention due to their low cost, natural abundance, excellent physicochemical and biological properties, and the intelligibility of the chemical reactions needed for specific modifications. Many polysaccharides contain various reactive functional collection (such as amino, hydroxyl, and carboxyl moieties), which can be readily utilized as active sites for drug combine, either directly or via linkers.

Properties of polysaccharide transporters

Polysaccharides are defined by their chemical structure, which consists of monosaccharide units joined together by glycosidic linkages.[11] They can be characterized according to their monosaccharide components, chain length, and chain branching pattern. The glycosidic bond within the anomeric carbon atoms of the acceptor and donor monosaccharide units distinguishes them from proteins and peptides. Polysaccharides, such as cellulose, have intrinsic storing qualities that give them physical shape and steadiness. Polysaccharides can be positively charged (like chitosan) or negatively charged (such as alginate, heparin, hyaluronic acid, and pectin) depending on the functional collection present.[12] Chemical modifications, comprising sulfation, phosphorylation, and carboxymethylation, alter the biological properties of polysaccharides,[13] making them valuable as drug transporters.

They also chose drug transporter due to their steadiness, non lethality, and biodegradability. Furthermore, chemical changes enhance the remedial effectiveness of the medicine via combine.[14] Drugs have poor immersion that are weakly soluble in aqueous solutions, interact with food, and degrade enzymatically, resulting in limited bioavailability.[15] Polysaccharide drug transporters boost the bioavailability of small molecules, proteins, and peptides by increasing their capacity to enter tissues due to their subcellular and submicron size.[16]

Upgrade cellular immersion in tissues inhibits first-pass metabolism and P-glycoprotein-

mediated efflux, while also facilitating intestinal lymphatic transport.[17] Polysaccharides' features, such as mucoadhesiveness, increased immersion, adaptability to chemical modification, biocompatibility, and low lethality, make them ideal drug transport techniques. aim-specific medication transport to the diseased site minimizes the drug concentration necessary for cure, his increases therapeutic influence and reduces adverse drug reactions by limiting drug distribution, thereby avoiding organs not involved in the diseased condition.[18]

Polysaccharides Based Drug Transporters

Polysaccharides are carbohydrates that have more than 10 monosaccharide units connected by a glycosidic bond. Polysaccharides, as natural polymers, have special qualities such as biocompatibility, steadiness, safety, sticky capabilities, attraction for certain receptors, and non- lethality, making them an important contender in drug transport organisations.[19] Polysaccharides exhibit significant structural and chemical diversity, as well as a variation of functional collection that allow for numerous chemical changes, hence improving their steadiness, solubility, recapitulation, and aim specificity. On the other hand, the presence of a large number of hydroxyl collection in the backbone of polysaccharides promotes the incorporation of particular ligands, creation in functionalized colloidal organisations.

Nauts et al. conducted the first study of the anti tumor capability of polysaccharides derived from B. prodigiosus (Serratia marcescens) toxins in 1946, suggesting that the microbes toxins could cause revocation in tumor patients.[20,21] Polysaccharide K (PSK) and polysaccharide peptide (PSP) are polysaccharides bound to protein derived from Coriolus versicolor that have been utilized as adjuvant immunotherapy for malignancies such as Polysaccharides are utilized in the cure of lung, breast, colorectal, and gastrointestinal tumors. Various polysaccharides utilized in drug transport organisations include alginates, chitosan, cyclodextrin, pullulan, dextran, guar gum, hyaluronic acid, pectin, and cellulose are employed in tumor cure.

Chitosan

Chitosan, the N-deacetylation result of chitin, a naturally occurring polysaccharide, is mostly found in the armor of arthropods, insects, and fungi. Chitosan is a linear polysaccharide composed of glucosamine and N-acetyl glucosamine units connected by -(1→4) linkages. Its distribution throughout the biopolymer chain can be random or block-like, depending on the extraction technique from chitin. The degree of deacetylation, defined as the molar ratio of glucosamine to N-acetyl glucosamine, is a crucial factor in determining its properties and

applications.

Chitosan may dissolve in acidic solution after deacetylation, and Chitosan is the only polysaccharide known for its high density of positive charges resulting from the protonation of amino collection on its backbone. Aside from its unique feature, chitosan has been shown to exhibit a variety of intrinsic qualities, comprising biocompatibility, non- lethality, and biodegradability.[22] Chitosan and its adjunct have sparked tremendous scientific interest and become one of the trendiest subjects in latest ages, particularly due to their dietary, medicinal, and pharmaceutical uses, such as nutrient[2-5] and medication transportation[6-9], as well as tissue engineering.[23,24]

Chitosan, an N-deacetylated is branch of chitin, is becoming increasingly popular as a macromolecular transporter due to its necessary features, comprising compliant and decomposability.[25] The cognizant amino moieties included in chitosan's backbone allow for the chemical coupling of a wide range of biological substances. Furthermore, like hyaluronic acid, chitosan has been shown to play an important part in tumor biology and may be employed to prevent tumour angiogenesis.[26] Given the chemical nature of chitosan, numerous adjunct, comprising glycol chitosan, N-succinyl chitosan[27] and carboxymethyl chitosan, have been employed in addition to non-modified chitosan. However, one of the most significant limits to the use of chitosan at pH 7.4. is its unsolvable. While nanoparticulate organisations have addressed this feature, numerous efforts have been undertaken to produce chitosan adjunct that are physiologically soluble, that may be employed in organisationsic tumor chemotherapy. Because of their recognized mucoadhesive nature and application in buccal drug transport organisations, Chitosan and its adjunct have been extensively employed for buccally administering weakly soluble anti tumor drugs, such as PTX and docetaxel (DTX). Low molecular mass chitosan (LMWC) is preferred for this purpose due to its higher solubility compared to high molecular mass chitosan.[28] These couples demonstrated equivalent in vitro and in vivo anti tumor activity and larger bioavailability (p.o.) than i.v. traditional drugs at the identical dose, as well as a longer circulation of blood time and less subacute lethal. One significant advantage of coupled LMWC is its ability to traverse the P-gp-mediated barrier (efflux pump) in the gastrointestinal tract, thereby bypassing cytochrome P450-dependent metabolism in the intestine and liver. Radiolabelled couples have also shown that LMWC-PTX was most likely captivated from the ileum and entered the organisation sic circulation of blood entire.[29]

Chitosan, a naturally occurring positively charged polysaccharide, is widely employed in biomedical research. Chitosan is the most abundant chitin adjunct, initiate in the cell walls of fungus, mollusc shells, and crustacean Armor. Chitosan is produced by deacetylating chitin under specific situation, with degrees of deacetylation ranging from 60% to 100%. The molecular mass of commercially generated chitosan ranges between 3800 to 20,000 Daltons.[30,31] Chitosan has (1 → 4)-2-acetamido-2-deoxy-β-D-glucan. (Nacetyl D-glucosamine) and (1 → 4)-2-amino-2-deoxy-β-D-glucan (D-glucosamine) units[32] Chitosan is a naturally occurring polysaccharide that is weakly water soluble but soluble in low pH solutions. To enhance its water solubility, various forms of chitin have been developed, comprising carboxymethyl chitin, fluorinated chitin, and sulphated glycol chitin. Several chemical modifications have been conducted to create numerous chitosan adjunct for controlled drug transport organisations. Chitosan exhibits antibacterial, antimicrobial, and anti-coagulant properties, and it also accelerates wound healing.[36] Chitosan with less molecular mass inhibits tumour development and exhibits anti-tumour activity while having a lower harmful affect on regular developing cells.[37,38] As a result, using less-molecular mass chitosan (LMWC) as a medication transporters can provide synergistic influences. Chitosan adjunct' anti tumor influences have been documented in a variation of tumor cell lines, which includes MCF-7, HeLa, and HEK293.[39] Chitosan contains various qualities that promote drug transport influence in the ocular, transdermal, and nasal routes, comprising cell permeability and mucoadhesion.

Chitosan with a positive charge was combined with negatively charged chemicals to create a variety of drug transporter organisations.[40] As a result, chitosan plays an important role in the transport of less-molecular- mass medicines and biomacromolecules. Chitin and chitosan adjunct show promise as polymeric transporter of anti tumor drugs. Chitosan's solubility and bioavailability can be enhanced by chemically modifying it.

Previous research has shown that derivatizing chitosan with an acetamido residue and an amino group improves the solubility of encapsulated medicinal molecules.[41] Some tumor cells are resistant to certain anti tumor medications, comprising cisplatin, docetaxel (DTX), methotrexate (MTX), and 5-fluorouracil.[42] Currently, traditional drugs have hazardous influences on various bodily organs, comprising the gonads, bone marrow, and gastrointestinal tract. Because of its stronger positively charged amino group, LMWC is especially drawn to the tumor cell membrane, which typically carries a higher negative

charge compared to normal cells. Additionally, chitosan has been demonstrated to attack tumor cells through electrostatic interactions with the tumour cell membrane. Moreover, chitosan-drug nanoparticles can serve as alternatives to conventional medications due to their selectivity for tumor cells and their biocompatibility.

Chitosan with Paclitaxel (PTX)

PTX, derived from Taxus brevifolia, is a powerful anti tumor cure for lung, breast, ovarian, and stomach tumors. However, PTX's aquaphobic properties and strong haemolytic lethal provide substantial challenges while drug distribution. mixing or uploading of PTX with biocompatible and biodegradable chitosan can boost PTX's water solubility and alleviate issues related with its aquaphobicity.[43] The PTX-chitosan combination is high influence in tumor cure than free PTX. The anti tumor impact of the PTX-chitosan complex was investigated in vitro in triple-negative breast tumor cell lines (MDAMB-231).[44] PTX attached to LMWC via a cleavable succinic anhydride linker increased its water solubility and showed comparable anti tumour to free PTX in tumor cell lines (NCIH358, SK-OV-3, MDA MB231). Furthermore, an buccally administered aqueous solution of the PTX-LMWC couples dramatically reduced tumour development in mouse having xenograft or allograft tumours.[45] Trimethyl chitosan PTX couples improved mucoadhesion and intestinal transit of PTX. Furthermore, folic acid functionalization enhanced the couple's anti tumor activity by increasing cellular uptake and intratumor accumulation.

Chitosan with Doxorubicin (DOX)

DOX is an anti tumor medication employed to cure bladder tumour, breast tumour, and lymphoma. Nonetheless, DOX induces cardio lethality and other adverse affects in the human body.[46] To minimize lethality, DOX had been coupled with chitosan using a cross-linking approach which enhances DOX's anti tumor performance at lower doses.[47] The cross-linking approach has been employed to link DOX with chitosan, thereby increasing anti tumor potency. The drug uploading organization was improved by combining tripolyphosphate with a chitosan-DOX mixture. The diameter of the chitosan-DOX complex ranged from 130 to 160 µm. In VX2 cells, the chitosan-DOX compound outperformed free DOX in terms of anti tumor influence.[48] DOX-loaded magnetic nanoparticles coated with chitosan quickly entered MCF-7 cells, gathered around the nucleus, and successfully administered doxorubicin. DOX-loaded nanoparticles served as a pH-dependent drug transport mechanism. Because they release the doxorubicin at pH 4.2, the medication can enter the tumour conditions.[49] DOX-

loaded cholesterol-modified glycol chitosan micelles coupled with folic acid produced considerable anti tumor counter to FR-positive HeLa cells.

Chitosan with DTX

DTX is a tumor cure agent employed to cure a variety of tumors, comprising, prostate tumor, breast, stomach and, non-small cell lung. Chitosan was converted into glycol chitosan, and DTX was uploaded onto the change to better version chitosan using the scission procedure. This couple's anti tumor activity was investigated in mice that carried A549 lung tumor cells. The DTX-loaded glycol chitosan nanoparticles exhibited lower lethality than free DTX. In lung tumor-bearing mice, DTX-loaded nanoparticles suppressed tumours more influence than free DTX.[50] Several investigations have found that a drug-loaded glycol chitosan nano-couple represents a promising nano preparations for tumor cure. DTX-loaded chitosan nanoparticles in a water-in-oil nano emulsion organisations have demonstrated enhanced anti tumor in a human breast tumor cell line. Furthermore, DTX-encapsulated chitosan nanoparticles have shown higher levels of Bax (a pro-apoptotic factor) compared to cells cured with free DTX.

Chitosan with MTX

The first need of MTX for tumor cure occurred in 1947. It is employed to cure leukaemia, breast tumor, and lymphomas, however it has nonspecific adverse influences. MTX has been linked with natural polymers like chitosan to minimize its lethality. Glutaraldehyde functions as a cross-linking agent to connect MTX and chitosan. The chitosan-MTX-TPP complex is formed through the ionic gelation of MTX, coupled chitosan, and sodium triphosphate. The anti tumor influence of chitosan-MTX coupling, tested in MCF-7 cells, showed that the coupled form of MTX was more potent and less toxic than free MTX. Erlotinib-loaded MTX-chitosan magnetic nanoparticles displayed temperature- and pH-dependent drug release. The specific uptake of MTX-chitosan magnetic nanoparticles through folate receptors positioned them as an intelligent transporter for intended cure in FR-positive solid tumours.

Chitosan with Curcumin

Curcumin is a potent anti tumor drug, but its main drawback is a poor pharmacokinetic profile. Chitosan-curcumin couple, formed by chemically conjugating curcumin to chitosan, considerably enhances curcumin solubility and steadiness via imine production. Under microwave irradiation, coupling occurs via imine connection within chitosan's amino group and the carbonyl group.[53] However, a recent work found that the use of a 1-ethyl-3 (3-

dimethylaminopropyl) carbodiimide spacer reduced steric hindrance in curcumin coupling, and the degree of substitution was boosted by utilizing acetate as a stimulus.[54] Encapsulating curcumin in chitosan nanoparticles could boost its anti tumor potency. Curcumin encapsulated with chitosan nanoparticles enhances its bioavailability and functions better than free curcumin. The anti tumor activity of curcumin-loaded chitosan complexes has been investigated in vitro in lung tumor. In vitro studies have shown that curcumin-loaded chitosan nanoparticles are more influence in inhibiting tumour development than free curcumin in breast tumor, hepatocellular carcinoma, and colorectal tumor.

Chitosan with Oxaliplatin

Oxaliplatin is a platinum-based chemotherapeutic agent employed in the cure of rectal and colon tumor. It inhibits either delays the increase of the tumor. Oxaliplatin was uploaded onto chitosan to create a pH-sensitive nano transporters enable intended transportation in tumour cells. Oxaliplatin-loaded chitosan nanoparticles enhance the influence of oxaliplatin in tumor cure. The pH-sensitive chitosan-oxaliplatin releases oxaliplatin significantly faster at pH 4.5 than at pH 7.4, which is crucial for tumour- intended drug transport.[55] The complex's anti tumor activity was investigated in MCF-7 cell lines. The chitosan-oxaliplatin combination activates the apoptotic cascade by increasing the production of cytochrome C, Bax, Bik, and caspases 3 and 9 in breast tumor cells. So, the oxaliplatin-chitosan combination could be a brilliant tumor cure strategy. Indeed, chitosan-based transporters hold promise as a strategy for delivering anti-tumor drugs.

Alginate

Alginate is a natural polysaccharide derived from brown seaweeds and marine algae such as Ascophyllum nodosum, Laminaria hyperborean, and Macrocystis pyrifera, accounting for up to 40% of the dry mass.[56] Alginate is a water-soluble linear polysaccharide composed of alternating blocks of 1-4 linked alpha l-guluronic (G-block) and beta-d-mannuronic acid (M-block) residues. These blocks are often arranged in an irregular block wise pattern with varying proportions of G-G, M-G, and M-M blocks. The carboxylic acid collection on these units confer a negative charge to alginate, enabling it to interact electrostatically with positively charged molecules, leading to gel formation. The gelation occurs as a result of the dimeric linkage of G-G blocks into "egg-box junctions" produced by multivalent cations. Even under extremely mild conditions, alginate can be readily cross-linked with non-toxic reactants, especially divalent cations like Ca2+, Sr2+, Zn2+, or Ba2+, with Ca2+ being the

most extensively studied. However, monovalent cations and Mg2+ ions are unable to form gels with alginate.[58] There are two gelation strategies for crosslinking alginate with polyvalent cations: exterior and internal gelation.[59] In external gelation, the alginate-drug solution is slowly dripped into a calcium salt (CaCl2) solution. For internal gelation, the alginate-drug solution is initially blended with an insoluble calcium salt (CaCO3), and the mixture is subsequently injected into an acidified oil phase. allowing Ca2+ to interact with alginate. However, the alginate-Ca2+ gel generated by these gelation techniques typically has a unbounded composition, resulting in drug lost while the gelation procedure, particularly for water-soluble medicines.[60-62] For example, the encapsulation of bovine methaemoglobin[63] and bovine serum albumin into alginate microspheres resulted in protein loss during the emulsification process due to migration from the internal to the exterior phase. As a result, certain adjustments have been made to this gelation process to improve drug transportation, such as the PEC within chitosan and alginate. The production of PEC is due to powerful electrostatic communication within chitosan amino collection and alginate carboxyl collection. The chitosan-alginate polyelectrolyte complex (PEC) is one of the most extensively studied types of alginate complexes. It has been prepared in various forms, comprising nanotubes, nano-/microparticles, beads/hydrogels, filaments, and 3D dimensional matrices, depending on the preparation process and preparations. PEC exhibits superior physicochemical properties and offers advanced biomedical applications compared to alginate-calcium gels and chitosan gels. The following sections will delve into the applications of chitosan-alginate PEC in different forms for drug transport.

Alginates are linear, unbranched anionic polysaccharides present in the cell walls of brown algae like Laminaria and Ascophyllum. They consist of (1 → 4′)-linked β-d-mannuronic acid and α-l-guluronic acid. Alginate finds primary application in food processing, pharmaceuticals, and industrial processes. Alginate has the prospective to be a useful drug transportation agent due to its qualities such as biocompatibility, bioavailability, low price, low lethality and medium gelation by the inclusion of divalent cations. Alginate has a wide range of applications, comprising cell transplantation, wound curing, and as a transporter for proteins, tiny chemical medicines. Alginate hydrogels are easily synthesized using the crosslinking process. Because of its bio-adhesive nature, alginate hydrogels would either verbally or inserted into the body straight. Alginate is widely employed in the pharmaceutical business due to its characteristics.[64] Alginate nanoparticles could be steadied by inclusion cationic polyelectrolytes.[65] Alginate's characteristics, comprising its ability to thicken,

stabilize, and form gels, make it an influence drug transporter. Controlled release medication transfer techniques is thought to provide stable and kinetically predictable medicine proclamation. Alginate, like hydrocolloids, has participated an important part in the development of controlled release result.

Alginate with DOX

Alginate is employed in anti tumor drug transfer organizations in a variety of techniques, comprising hydrogels, nanogels, and nanoparticles, because of its biocompatibility besides biodegradability.[66] Alginate nanoparticles was made with gelling alginate and bivalent cations like calcium and then loading it with DOX.[67] DOX has an stronger attraction for alginate polymers. Alginate nanoparticles are employed as medication transporters because of its large DOX uploading capability. That may be extra than 50 mg for every 100 mg of alginate. DOX-loaded nanoparticles had been shown in experiments for curing liver metastases in mice. DOX-loaded alginic acid/poly(2-(diethylamino)-ethyl methacrylate) nanoparticles were evaluated in H22 tumor-bearing rats. Alginate nanoparticles demonstrated increased absorptivity and preservation, passively pointing tumor cells, as proven by near-infrared (NIR) fluorescence tomography techniques. In H22 tumor-bearing mice, an intravenously administered DOX-loaded alginic acid/poly(2-(diethylamino) ethyl methacrylate) (ALGPDEA) nanoparticle suspensions outperformed free DOX cure.[68]

Alginate with Curcumin

Curcumin is a polyphenol found in nature substance castoff to cure a variety of malignancies, comprising prostate, bladder, cervical, and breast tumor.[69] But, the main issue is limited water solubility also weak bioavailability. Encapsulating curcumin in aquaphilic calcium alginate nanoparticles can help improve its steadiness and bioavailability, allowing for intended transport to specific sites in the body. Alginate's entrapment effectiveness for curcumin was 49.3 ± 4.3 percent. The curcumin-loaded calcium alginate nanoparticles were created using an emulsification and cross-linking process. The atom proportions were determined to be 12.53 ± 1.06 nm. An alginate nano preparations were tested in prostate tumor besides shown lethal possessions on DU145 prostate tumor compartments in vitro.[70] Furthermore, coupling with alginate greatly increased curcumin's water solubility. The couples were formed by esterifying curcumin's hydroxyl group with sodium alginate's C-6 carboxylate assembly. The anti tumour tests employing L-929 murine fibroblast cells indicated that the anti tumour likely of curcumin were maintained even later coupling.[71]

Alginate with Exemestane (EXE)

EXE is a potent aromatase inhibitor that is aquaphobic and exhibits significant lipophilic properties. It has shown favourable solubility in organic solvents. EXE, an buccal chemotherapeutic agent, primarily combats breast tumor by reducing estrogen production.[72] That is uploaded into alginate nanoparticles using easy contained gelation procedures. Loading and unloading were verified through X-ray diffraction (XRD), scanning electron microscopy (SEM), and Fourier transform infrared spectroscopy (FTIR) techniques. The XRD measurements were carried out to verify the EXE encapsulation.[73] The preparation's anti tumor activity was investigated in vitro on DLA cells (Dalton's lymphoma ascites). EXE was unrestricted since the nano preparations in vitro at pH 7.4, and the controlled release of EXE packaged in alginate nanoparticles reduces chemotherapy side influences. Therefore, in vitro investigations have indicated that the EXE–alginate nano preparations holds promise as a potent anti tumor agent.

Alginate with Tamoxifen (TMX)

TMX was employed extensively to cure breast tumor.[74] Its solubility in water is limited, that limits buccal transport of medication. That challenge could solved using a nanoparticle transporter technology for drug transport. Nanoparticles containing bovine serum albumin besides thiolate alginate were produced using the coacervate process and encumbered with TMX. In vitro release studies of this preparations revealed a TMX release ranging from 45% to 52% over a period of up to 25 hours. Cellular uptake of TMX-loaded nanoparticles was examined in monocultures of MCF7 and HeLa cells. The TMX-loaded alginate nanoparticles demonstrated influence in both cell lines. Additionally, folate- intended alginate-silver nanoparticles coated with TMX displayed enhanced anti-tumor influences in breast tumor cell lines. These influences were achieved by inducing ROS, downregulating survival oncogenic genes such as BCL-2 and survivin, and arresting the cell cycle at the G2/M phase.

Pectin

Pectin is a linear polymer that is present in larger concentrations in plants' middle lamellas.[76] Pectin consists of D-galacturonic acid (GalA) units linked by α (1 → 4) glycosidic bonds. It forms a homopolymer composed of (1 → 4) α-D-galactopyranosyluronic acid units, with varying degrees of methyl esterification on the carboxyl collection. The pectin backbone also contains rhamnose, whereas the side chain contains galactose, xylose, and arabinose.[77,78] Pectin's most important trait is its capacity to produce gels. Because of its feature, employed

in utilized in the nutrition and pharmacological sectors. The primary source of pectin is plant residue left after juice extraction. Citrus fruit peels contain approximately 20-30% pectin, while apples contain around 10-15%. Other sources of pectin include beans, mango trash, sunflower heads, cabbage, and sugar production waste. Because of its ability to form gels in acidic environments, pectin has long been utilized as a medicine transporter. The gel-forming capability of pectin varies depending on its molecular composition, molecular mass, and source. Pectin is extensively utilized as a food additive and is considered entirely safe for consumption. Pectin is now employed as a medication transporter due to its beneficial qualities like non lethality, bioavailability, besides less production price. There various modalities of transport, as well as nasal and buccal direction. Pectin's carboxylic acid functional group allows it to easily couple with the amino collection of anti tumor medicines.[79] The antitumor drug from the pectin couple is rapidly released within the tumor cell due to the facile hydrolysis of the amide bond by lysosomal enzymes.

Pectin, a significant element of all higher plant cell walls, is a naturally occurring carbohydrate that is plentiful and widespread. Pectin denotes to a group of oligosaccharides and polysaccharides that have mutual properties, although their fine structure varies depending on the source. Although pectin's chemical structure is exceedingly variable and intricate, it is often rich in 1,4-linked alpha d-galactosyluronic acid residues, with acetyl and methyl esterified carboxyl sets forming a linear chain.[80] The functional characteristics of it are influenced by the level of methyl esterification and acetylation. Its most attractive feature is its ability to form gels, making pectin widely employed in the food industry as a gelling agent and stabilizer since the 1800s. From the 1990s onward, extensive research has for employed on pectin's application in pharmaceuticals, particularly in colon-specific drug delivery and encapsulation. Pectin molecules remain intact in the gastrointestinal organisations but degrade in the colon due to pectinolytic enzymes and bacteria. However, its high solubility poses challenges for transporting encapsulated medicines through the stomach and small intestine. To address this, pectin adjunct with low water solubility, like calcium pectinate and amidated pectin, are utilized, along with coating materials, particularly chitosan, to create controlled-release pectin-based transport organisations. Pectin is primarily recognized for its resistance to digestion in the gastrointestinal tract, yet it can be broken down through fermentation in the colon. Consequently, significant research has been conducted to develop transport organisations intended for the colon. The chitosan-pectin PEC combines the strengths of both components, offering distinct advantages as a colon- intended

drug transport organisations. This includes robust electrostatic crosslinking in the stomach to prevent particle dissolution, as well as high resilience to enzymatic hydrolysis, ensuring sustained drug release until reaching the colon.

Pectin with Curcumin

Curcumin is extracted from turmeric rhizomes besides utilized as an anti-inflammatory, antibacterial, antiviral agent, and anti tumor agent.[85] Curcumin exhibits remarkable hepatoprotective properties.[86] Curcumin is an excellent anti tumor medication applicant due to its antioxidant and anti-inflammatory characteristics, however inadequate immersion is the primary issue when buccal dispensation. That issue could addressed with creating right curcumin nano preparations by pectin. Curcumin demonstrates the ability to impede the development of human colon tumor by modifying the NF-κB signalling pathway. Studies have shown that curcumin-loaded pectin exhibits a stronger anti-tumor influence in colon tumor (HCT116) compared to free curcumin. Pectin acts as a carrier, preserving curcumin's integrity and bioactivity while facilitating intended delivery to colon tumor cells. Additionally, pectin-type B gelatin curcumin couples have proven to be more efficacious in distributing curcumin through buccal administration as anti-tumor drugs. These couples are formed through an esterification process between the carboxylic collection of pectin and the phenolic -OH group of curcumin. Investigations into the anti-tumor properties of these couples have demonstrated significant suppression of KYSE-30 cell lines when compared to free curcumin.

Pectin with DOX

Pectin has been employed as a transporter for anti tumor medicines like DOX. Pectin was thiolate-linked with DOX to generate thiolate pectin-DOX couple, with The anti-tumor influence of thiolate pectin-DOX coupling was investigated in human prostate tumor, human bone osteosarcoma cells, and colon tumor in vitro. In the case of 143B and CT26 cells, the coupling exhibited greater anti-tumor activity compared to free DOX, but no significant difference was observed between free DOX and thiolate pectin-DOX in prostate tumor cells. Thiolated pectin-DOX couples have been utilized for intended drug delivery in CT26 cells. Additionally, self-assembled DOX-coupled aquaphilic pectin nanoparticles loaded with aquaphobic dihydroartemisinin demonstrated a rapid and mild release of DOX and DHA.

Pectin with Cisplatin

Cisplatin is an anti tumor medicine expended to cure a variety of tumors, comprising lung, head and neck, ovarian, and bladder tumor.[92] Cisplatin can be employed alone or in combination with other tumor cure like radiotherapy. Pectin couples with cisplatin were investigated in vitro in B16 cells (murine melanoma). These in vivo experiments demonstrated anti tumor influence in rats. The anti-tumor influence was assessed by assessing tumor development. Tumor regression studies[93] found that cisplatin significantly reduced tumor size. When combined with radiation, pectin nano couples and cisplatin were more influence than cisplatin alone. Pectin-cisplatin nano-couples exhibited an extended blood retention profile in mice, as confirmed by the detection of cisplatin in the bloodstream even after 24 hours. When J-774 cells were incubated with the nano-couples labelled with FITC, approximately 40% of the cells showed uptake within 30 minutes of incubation.

Guar Gum

Guar gum, a naturally occurring high-molecular- mass, uncharged carbohydrate, is predominantly found in Cyamopsis tetragonolobus. It consists of galactomannan, a polymer containing galactose and mannose. With its numerous hydroxyl collection, guar gum is well-suited for derivatization. It is widely utilized as a stabilizing and emulsifying agent. Guar gum's key feature is its swelling property, which is utilized to limit medication release. Guar gum is water soluble, then not soluble in hydrocarbons, lipids, alcohol, esters, and ketones.[95] Frequently, it yields a dense colloidal solution in both hot and cold water. Guar gum's steadiness, non- lethality, and biodegradability make it useful in a variety of medicinal applications, most notably drug administration. Guar gum and its adjunct are employed as medication transporters in intended drug transport organisations. Guar gum has been employed to manage the release profile of medications which are very water soluble and difficult to distribute to the aim site.[96]

Guar Gum with 5-Fluorouracil (5FU)

5FU is a medication employed to cure colon tumor.[97] 5FU is weakly immersed after buccal dosing, resulting in limited bioavailability. To increase bioavailability, a microsphere made of guar gum and sodium borate was created using the emulsification cross-linking technique. That assisted to limit the drug's delivery over 24 hours, precisely in the colon, and it was more influence counter to colorectal tumor. The microspheres loaded with 5FU exhibited enhanced steadiness, and the release of 5FU followed zero-order kinetics, involving both degradation and erosion mechanisms. These microspheres were capable of delivering the

maximum amount of medication in a controlled manner specifically for colon tumor cure. The pH range in the colon is roughly 5.5-7, and there is slight gastrointestinal enzymatic action, which promotes higher medication immersion. The influence of preparations in colon-intended buccal medication transport organisations has been investigated in vivo.[98]

Guar Gum with Tamoxifen Citrate (TMX)

TMX has an antagonistic influence breast tumor cells then utilized to cure ER (+) tumors.[99] The emulsion technique produced guar gum containing TMX nanoparticles. Guar gum has is employed as a medication transporter for a variety of anti tumor medicines, although slight data is available regarding its nano preparations. Guar gum nanoparticles coated with TMX were tested on albino rat for 2 days. After 2 days, nanoparticles are identified in mammary also ovarian tissue, then nanoparticle acceptance and retaining were greater in mammary glands.[100]

Guar Gum with MTX

Guar gum microspheres were produced and utilized to cure colorectal tumor.[101] The trapped effectiveness of MTX-loaded microspheres was determined to be 75.7%. Guar gum microspheres supplied the most medication to the intended spot in colon tumor. The preparations were administered buccally to albino rats, and drug release was monitored in different regions of the body, including the stomach, colon, and small intestine, at different time intervals. The research revealed that guar gum microspheres released MTX specifically at the aimed region in the colon. Consequently, guar gum microspheres have been utilized as an effective MTX transport vehicle in the treatment of colorectal tumors.

Guar Gum with Curcumin

Curcumin have employed as an anti tumor medicine because of its antioxidant qualities, however the main issue is low immersion in the GI tract.[103] To address this issue, curcumin was mixed with guar gum at various concentrations, and the preparations were tested for their influence on colon tumor. The drug release of the preparations containing 40% guar gum was 91.1%, while the 50% guar gum containing preparations had a drug release of 82.1%, which was lower than the 40% guar gum preparation . Guar gum's influence and drug release analyses counter to colonic microbes are investigated using mice cecal fillings. Guar gum may be an influence medication transporter for curcumin administration in colon tumor.

Dextran

Natural polymers are employed as transporters in medication transport organisations because they are non-toxic also inexpensive to produce. Dextran is a natural polymer employed in intended drug transport organisations[104] with a monomeric α-D-glucose unit and α- (1 → 6) glycosidic linkage in the backbone. Dextran finds extensive use in the pharmaceutical, food, and chemical industries as a transporter, stabilizer, and emulsifier. Its biocompatibility, non-immunogenicity, and non- lethality have made it a valuable component in drug transport organisationss. It is also simply changed and thus commonly employed in drug transport organisations. It boosts the drug's constancy also keeps it gathering in the blood.[107] Dextran slows tumor development and decreases the lethality. Dextran holds promise as a drug transport agent for anti-tumor medications.

Dextran, another extensively employed macromolecule in anti tumor drug coupling techniques, contains monosaccharides of the plain sugar glucose. Initially approved as a plasma expander, this poly-glucose biopolymer possesses favourable physicochemical properties, along with low cost and a well-established clinical history, rendering it an attractive choice for drug transport applications. While dextran sulphate has been utilized in conjunction with positively charged anti-tumor drugs owing to its polyanionic structure, the dextran backbone contains numerous primary and secondary hydroxyl collection that deliver possible functional locations for drug coupling via direct or indirect techniques. Several anti-tumor medications, including doxorubicin (DOX), CPT, mitomycin C (MMC), and methotrexate (MTX), have been linked to dextrans to form anti-tumor drug conjugates. In drug transport, at least three dextran adjuncts have been utilized: carboxymethyl dextran, oxidized dextran, and amino-dextran. A lot of in vitro and in vivo studies found that these couples had a longer impact and lower lethality and immunogenicity. Carboxymethyl (CM) dextran contains a significant number of carboxyl moieties, providing ample coupling sites for the attachment of polymer drugs, resulting in water-soluble CM dextran-drug conjugates. Peptidyl spacers are commonly used for the indirect coupling of dextrans. These linkers serve as substrates for lysosomal cysteine proteinases, particularly cathepsin B. The choice of peptidyl linkers plays a crucial role in determining the success of the conjugates in mice xenograft models and clinical trials. Although most dextrans investigations have not gone beyond the preclinical stage, oxidized dextran-doxorubicin couples (AD-70) have begun Phase 1 clinical trials. Unfortunately, this alteration produced a non-biodegradable polymer with lethality, that was related to dextran immersion through human liver reticuloendothelial cells. In Phase 1 clinical studies, another dextran-drug compound (DE-310) using CM

dextran as the polymer demonstrated dose-restrictive lethal such as thrombocytopenia, neutropenia, and changeable hepato lethality. However, Among the patients, one achieved complete remission, one experienced partial remission, and 14 demonstrated disease steadiness, all in the context of metastatic adenocarcinoma of unknown origin. Another carboxymethyl dextran-CPT adjunct combination, Delimotecan, showed limited reactions in individuals by anal tumor and head and neck tumor.

Dextran with DOX

Dextran is an excellent transporter in drug transport organisations, enhancing the steadiness of DOX.[108] Combinations of dextran-DOX and dextran-CPT demonstrated exceptional anti tumor action counter to the 4T1 cell line and 4T1 tumor-bearing rat when related to the unrestricted medications.[109] A biocompatible poly prodrug, derived from dextran-DOX prodrug (DOXDT), was synthesized using one-step atom transfer radical polymerization (ATRP). DOXDT prodrug has a larger drug loading capacity than other lipid-based drug transport techniques, with a maximum of 23.6%. The DOXDT exhibits increased anti tumor counter to 4T1 and HeLa cells. DOXDT was also researched for its cancer-suppressive properties. The DOXDT-based transport device inhibited the development of tumor cells.[110]

Dextran with PTX

PTX, also known as Taxol (TXL), is an anti tumor medication employed to cure breast, ovarian, and lung tumor. TXL and its adjunct were coupled with aminated dextran to generate dextran-TXL couples, which were tested for anti tumor influence on HeLaKB cells in vitro. When combined with folic acid, Dextran-TXL couples demonstrated two to threefold enhanced anti tumor activity. So, conjugating TXL with dextran and folic acid may boost Taxol's anti tumor activity.[111] A Dex-SS-PTX combination exhibited substantial anti tumor in BT-549 and MCF-7 cells.[112]

Dextran with Phenoxodiol (PXD)

PXD is a artificial counterpart of the plant isoflavone genistein that has a higher anti tumor activity.[113] PXD, an anti-tumor drug, was coupled with dextran to increase its influence.[114] The couple's anti-proliferative influence was investigated in glioblastoma, breast tumor MDA-MB-231, and neuroblastoma SKN-BE (2)C cells. Additionally, the anti-tumor efficacy was assessed in both HMEC-1 (human microvascular endothelial cells) and non-malignant human lung fibroblast MRC-5 cells. This couple outperformed the free medication in terms of steadiness, influence, and safety.[115]

Dextran with MTX

MTX is prescribed to cure tumor and other hematological disorders. To improve the drug's preparations, MTX is covalently linked to dextran.[116] The couple's anti tumor activity was assessed in human brain cancer (H80) and 9L gliosarcoma in mice brains. The combination destroyed cancer cells more efficiently than free MTX.[117]

Dextran with Curcumin

Curcumin is widely employed in tumor cure because of its well-known biological characteristics. A research with carboxymethyl dextran-coated liposomal curcumin found that it boosted anti tumor and cellular immersion in HeLa cells.[118] Dextran-curcumin micelles (Figure 6) formed by self-assembly of dextran curcumin coupling, demonstrated significant anti-tumor activity in tumor cells attributed to enhanced solubility and increased cellular uptake related to free curcumin.[119] Curcumin has been influence coupled with dextran using a free radical process. The anti tumor influence of curcumin-dextran combination was investigated in MCF-7 and adenocarcinomas stomach cell lines using the MTT evaluate. Curcumin-dextran couples inhibit proliferation in MCF-7 cell lines and human gastric tumor cells.[120] Curcumin-dextran couples operate as a transporter for MTX and work synergistically to improve the anti tumor influence in MCF-7 cell line.[121]

Dextran with Exatecan

Exatecan has been utilized in clinical studies for the cure of sarcoma, lymphoma, lung tumor, leukaemia, and liver tumor, among other conditions. Exatecan is a structural analogy of camptothecin that has antineoplastic properties. The linker needed for coupling is Gly-Gly-Phe-Gly. The types of bonds produced are amide with medication and amide with polymer. A solo dose of the coupling (DE-310) had comparable or better anti tumor influence than several dispensations of DX-8951f (different human cancer xenografts and murine solid cancer).The approximate molecular mass of couple is 360kDa.

Hyaluronic Acid (HA)

Hyaluronic acid is a negatively charged biopolymer composed of interchanging disaccharide units of d-glucuronic acid and N-acetyl-d-glucosamine, linked by (1→4) interglycosidic connections. It is frequently employed in drug transport requests because of its wide range of biological functions, outstanding physicochemical properties, compatibility with living organisms, ability to break down naturally, and lack of immune response. Elevated HA levels

have been deemed a valid disorder development indicator in various kinds of malignancies, comprising bladder tumor. Even though high molecular mass hyaluronic acid (HA) has been utilized in medical settings for its physical attributes, such as lubrication in eye surgeries and knee issues, low molecular mass HA and its smaller fragments are significantly involved as active agents in tumor biology. This highlights the significance of selecting the molecular mass of bioactive polysaccharides in the design of anti-tumor drug transport organizations. Studies have shown that HA oligomers consisting of 8-50 disaccharides, unlike high molecular mass HA, promote angiogenesis. The capability of HA to actively aim without the use of additional aiming ligands is perhaps its most surprising advantage. Hyaluronic acid has a high attraction for cell-definite superficial indicators comprising CD44 and RHAMM, which has sparked a lot of attention. CD44 is a cell superficial protein that performs as a particular film receptor for HA. It is upregulated in numerous tumor cells and tumor stem cells, and its presence has been associated with the invasive characteristics and metastatic mechanisms of these cells. As a result, breast tumor cells preferentially absorb HA over normal tissue As a result, by conjugating anti tumor medicines, these HA-based organisations shift the organisations of dose immersion from non- definite interest to receptor-mediated endocytosis. Because of the rising evidence of CD44 expression on tumor stem cells, the possibility of selectively directing chemotherapeutic drugs to CD44 has piqued researchers' curiosity. Furthermore, studies have revealed that endogenous HA is essential for increased p-glycoprotein production, which is the basic cause of medicine repealing. Research has shown that the direct interaction between CD44 and p-glycoproteins inside the cell can lead to the overexpression of one while impacting the other. It's been suggested that by disrupting the constant HA-CD44 complex with a competitive antagonist, tumor cells could become more responsive to anti-tumor drugs by reversing multiple drug resistance mediated by p-gp. Thus, hyaluronic acid-drug couple might be reflected an antagonist that increases the susceptibility of drug- repeal cells to the anti tumor therapeutic molecule. The hydroxyl and carboxylic collections on the hyaluronate support make good locations for drug coupling. . Direct drug coupling to HA is in influence because of backbone steric hindrance also limited carboxylate group responsiveness. In indirect coupling, HA can be widely adjunct with adipic acid dihydrazide (ADH). This approach creates responsive functional assemblies (NH2-NH2) that permit additional particles to connect to the HA support. Furthermore, The employment of adjuncts such as HA-ADH allows for regulating the extent of substitution (DS) of carboxylic acid, which plays a crucial role in the energetic aiming capabilities of HA. It is discovered that DS concentrations more than 25 mol% can reduce the capacity of HA to aim

CD44. In that situation, adequate anti tumor by HA-drug couples is attained as soon as a stability is struck within nominal HA alteration and maximum dose uploading. It was demonstrated that large PTX uploading occluded the CD44 credit fundamentals of HA, causing couple accumulation and thereby limiting couple lethality in comparison to free PTX. A novel technique to limiting drug replacement in HA-drug couples was projected. 6-Amino-6-deoxyhyaluronan was produced as an intermediary for coupling with CPT. Because CD44 recognition does not rely on HA's C-6 hydroxyl collection, higher degrees of substitution may not affect the targeting capabilities of the resulting complexes. Given HA's limited solubility in most organic solvents and the aquaphobic nature of many anti-tumor drugs, its aquaphilicity restricts its interaction with these medications. To address this challenge, various solubilization techniques have been employed to achieve a uniform mixture of HA and aquaphobic reactants in a single solvent. Methods such as nano-complexation with dimethoxy polyethylene glycol and ion pair complexes involving long aliphatic chain cationic salts have been utilized to enhance solubility in polar organic solvents or mixtures of water and polar solvents (e.g., DMSO/H2O or DMF/H2O). Finally, a variety of HA-drug couples were synthesized using the procedures described above and evaluated for anti tumor in vitro. These research produced partially contentious information on several cell lines. It was hypothesized by enhancement in anti tumor of HA-drug couples relative to unrestricted dose is owing to higher water solubility and cell internalization capability of the couples, whereas the described Reduced impact, including on CD44+ cells, might be associated with a decrease in the availability of unbound anti-tumor molecules that are linked together. Although various approaches to developing a potential anti tumor-drug couple have been evaluated (Table 2), The sole couple form of high molecular mass HA-PTX, pioneered by an Italian research group, has progressed to clinical trials. The compound was proven to have slight lethality and no complete immersion following intravenous instillation for noncompliant bladder tumor (Bassi et al., 2011). Including aiming ability, upcoming applications of hyaluronic acid in anti tumor medication coupling appear to be attention employed on improving the coupled drug's biodistribution and pharmacokinetics following organisation transport.

Hyaluronic acid (HA), also known as hyaluronan or hyaluronate, is a naturally existing polysaccharide that is non-toxic, biocompatible, and biodegradable. It is unique among glycosaminoglycans in that it lacks sulfation and consists of repeating disaccharide units, specifically -1,4-d-glucuronic acid--1,3-N-acetyl-d-glucosamine. HA occurs naturally in the

body with a broad molecular mass range, from 100k Da in serum to 8000k Da in vitreous.[122] HA is found in all tissues of existing creatures, comprising connecter, epithelial, and neuronic tissues. Because of the carboxyl collection on the backbone, It's a naturally occurring ionic polysaccharide that has been extensively studied for its potential in forming PEC (polyelectrolyte complex) nanoparticles when combined with cationic biopolymers the most common of which is chitosan. PECs based on HA have shown promise as biological materials due to their ability to be customized in terms of size, their colloidal stability, low anti-tumor properties, and protection from enzymatic degradation, among other factors (reference 123).

HA with PTX

PTX is sourced from the bark of the Pacific yew tree and possesses antimitotic properties. PTX is an anti tumor drug that increases tubulin association. PTX has been chemically modified through esterification with hyaluronic acid. It suppresses cell multiplication during the delayed G2/M stage.[124] Initially, hyaluronic acid was dissolved in DMSO along with polyethylene glycol (PEG), and subsequently, it was coupled with PTX through an ester linkage without any further modifications.[125] The HA-PTX couple produces micelles in aqueous solution. Tumor cells exhibit an overexpression of the hyaluronic acid receptor. As a result, the HA-PTX compound demonstrates greater binding affinity and anti-tumor effects in tumor cells compared to normal cells. In vitro, this compound demonstrated anti-tumor influence in MCF-7 and HCT-116 tumor cells.[126] Chitosan-coated HA–PTX nanoparticles were synthesized by applying chitosan onto the surface of self-assembled HA–PTX complexes (refer to Figure 7). These HA–PTX nanoparticles exhibited increased cellular uptake compared to free PTX when tested in HepG2 cell lines.

HA with DOX

DOX is beneficial for curing ovarian, multiple myeloma, breast, and paediatric solid tumors.[128] DOX has been conjugated with hyaluronic acid through an amide linkage between the carboxylic acid group of HA and the amine of Dox, forming an amide bond and a nano-conjugate with enhanced anti-tumor activity. The anti tumor influence of the hyaluronan-DOX nano couple was investigated in MDA-MB-231 breast tumor cell lines. The nano-couple increased anti tumor in breast tumor cell lines. The combination exhibited less lethality to usual cells. The nano-couple also suppressed breast tumor in vivo, increasing survival rates. The nano couple reduced tumor development in the early stages of breast

tumor.[129]

HA with Cisplatin

Cisplatin is commonly prescribed to cure bone and blood vessel tumor. Cisplatin is a powerful anti tumor mediator, though the usage is restricted because of toxic influence on the neurological organization. Cisplatin was combined through hyaluronic acid to generate a low poisonous compound with enhanced tumor- intended transport, reducing its negative impact. The couple was administered to squamous cell carcinoma of the head and neck in vivo to evaluate its anti-tumor ability. The outcomes reveal that the couple has better anti tumor activity while causing less lethality. The couple's anti tumor influence is too demonstrated in dogs with smooth tissue carcinoma.[130]

HA with Camptothecin (CPT)

CPT (camptothecin) is derived from Camptotheca acuminata, a tree native to China, and possesses anti-cancer properties by inhibiting nuclear enzymes. CPT is an alkaloid with low water solubility, resulting in reduced cellular immersion. Numerous CPT similarities have designed for address an issue also increase water solubility.[131,132] 7-ethyl-10-hydroxy camptothecin, an analog of CPT, has been conjugated with hyaluronic acid to create ONCOFID-S. Its anti-tumor properties have been studied in breast, esophageal, ovarian, gastric, and lung tumors (reference 133). ONCOFID-S has shown anti-tumor activity in mice with peritoneal carcinomatosis induced by esophageal, colorectal, and gastric adenocarcinomas (reference 134).

HA with Sodium butyrate

Sodium butyrate is a compound with the chemical formula Na(C3H7COO). It is the sodium salt of butyric acid. There is a variety of influences on cultured mammalian cells, comprising reduction of explosion, initiation of variation, and activation or suppression of gene expression. Hence it employed in the laboratory to produce any of these influences. Cure with butyrate leads to histone hyperacetylation, as butyrate inhibits the activity of class I histone deacetylases (HDACs), particularly HDAC1, HDAC2, and HDAC3. This inhibition can be utilized to investigate histone deacetylation in chromatin structure and function. It is estimated that inhibiting HDAC activity affects only 2% of mammalian gene expression. The HA and sodium butyrate are directly coupled, establishing an ester link. The couple's approximate average MW is 85166 kDa. The difference in molecular weight did not affect the biological activity of the compounds through CD44 in MCF-7 cells.

HA with curcumin

Curcumin is a diarylheptanoid which fit in to the curcuminoids family of phenolic pigments that give turmeric its yellow hue. Curcumin has been examined in a variety of human carcinomas, comprising head and neck, melanoma, pancreatic, prostate, breast, colon, and ovarian tumors. Epidemiologic studies link India's less colon tumor occurrence to the chemo protective also antioxidant capabilities of curcumin-rich diets. Curcumin's anti tumor actions are complex and varied, affecting several stages of control in cellular development and death. The couple has an approximate average molecular mass of 560 kDa. Direct coupling occurs between HA and curcumin, resulting in the formation of an ester bond. Improved anti tumor owing to water solubility ell internalization ability of the couple.

Cyclodextrin

Cyclodextrin (CD), which consists of cyclic oligosaccharides, features a aquaphilic superficial layer composed of (α-1,4)-linked α-D-glucopyranose units and a lipophilic core cavity (reference 135). Cyclodextrins are biocompatible, exhibiting less lethality and immunogenicity. Their molecular mass ranges from 1000 to 2000 Da. Examples of natural cyclodextrins include α-cyclodextrin (αCD) with six glucopyranose units, β-cyclodextrin (βCD) with seven glucopyranose units, and γ-cyclodextrin (γCD) with eight. β-cyclodextrin is the maximum often employed cyclodextrin in the pharmacological business due to its less manufacture price, high bioavailability, and ideal cavity proportions. Cyclodextrins create water-soluble complexes with numerous weakly soluble chemicals. Cyclodextrins are hollow and truncated, featuring a cavity that is somewhat aquaphobic internally and aquaphilic externally. Drugs with aquaphobic properties can be readily enclosed within the cavity of cyclodextrins, forming an inclusion complex without undergoing any chemical reaction. Consequently, encapsulating the aquaphobic medication in cyclodextrin improves its stability and aqueous solubility. Cyclodextrin also exerts a protective effect, reducing the drug's adverse effects on the human body (reference 136).

Even though there are few publications of usage of cyclodextrin polymer, It could be considered one of the most impactful polysaccharides for drug conjugates in terms of design and optimization studies aimed at achieving CRLX101. CRLX101 (previously IT-101) is a polymeric nanoparticle preparations consisting of 30-40 nm elements made of CPT covalently attached to a linear -cyclodextrin-polyethylene glycol copolymer. CRLX101 underwent Phase 1 clinical trials have been undertaken for the treatment of advanced solid

tumors., with several animal studies demonstrating its anti tumor ability and suitable safety profile. IT-101 has a half-life of approximately 40 hours in humans. Conferring to Phase I clinical trial data, Phase II trial has begun to evaluate the influence in ovarian tumor.

Cyclodextrin with DOX

The anti-tumor medication DOX was encapsulated in pegylated liposomes and coupled with γ-cyclodextrin. It was examined for its anti tumor influence in BALB/c rat carrying colon-26 cancer cells. The anti-tumor action was related in various couples, comprising pegylated liposomes entrapping DOX, γ-CD, and the binary organisations of liposomes containing both DOX and CD and unrestricted DOX. Several arrangements have been tried in rats, and outcomes suggest that the composite-in-liposome containing DOX and CD delivered higher DOX levels in plasma and solid cancer than the another preparations. Pegylated liposomes containing DOX and γ-CD inhibited cancer development and increased mouse existence rates, enhancing DOX's anti tumor influence.

Cyclodextrin with CPT

CPT is a aquaphobic anti tumor medication, but then its therapeutic use is limited because of features like in steadiness in physiological circumstances also low solubility in aqueous solutions. Nanoparticulate organisations comprising poly-epsilon-caprolactone, amphiphilic cyclodextrins, or poly(lactide-co-glycolide) (PLGA) exhibit enhanced solubility and steadiness.[137] Amphiphilic cyclodextrin nanoparticles had higher dose-uploading size and anti tumor activity than other nanoparticles. The anti-tumor influence of nanoparticles was investigated using the breast tumor cell line MCF-7. CPT-uploaded cyclodextrin nanoparticles verified that is moral transporter technique for efficient CPT administration.[138]

Cyclodextrin with Curcumin

Curcumin is employed as an anti tumor drug, but its weak buccal bioavailability is a serious issue which is addressed by conjugating by cyclodextrin.[139] The curcumin-cyclodextrin combination is studied for several anti tumor investigations. For 1 investigation, curcumin was enclosed in the β-cyclodextrin void with the saturated aqueous solution technique. Cyclodextrin improved curcumin distribution, increasing its therapeutic influence in vitro. It affected multiple pathways, comprising up-guideline of p53/p21, down-guideline of CyclinE-CDK2, increased expression of MAPK/NF-κB pathway, Bax/caspase 3, and CD15. The cyclodextrin-curcumin combination has employed to increase curcumin's anti tumor activity and transport in lung tumor.[140]

Cyclodextrin with PTX

PTX is prescribed to cure lung, breast, bladder, oesophagus, and ovarian tumor. There solubility in aqueous solution is quite poor, that poses a significant challenge in cure. The difficulty could solved with conjugating PTX with cyclodextrin. The anti tumor influence of the PTX-cyclodextrin combination was demonstrated in MDA-MB-231 breast tumor cells.[141] The PTX-loaded cyclodextrin peptide (R8-CMβCD) enhanced PTX absorption by inhibiting the P-gp efflux pump in tumor cells. PTX-linked β-cyclodextrin polyrotaxane significantly inhibits tumor growth and prolongs the survival of tumor-bearing rats.[142,143]

Pullulan

Pullulan is a natural biopolymer made up of maltotriose units connected by α (1 → 4) glycosidic bonds. Following, subsequent maltotriose units are connected by α (1 → 6) linkages. Pullulan originates from the fermentation broth of Aureobasidium pullulans.[144] Pullulan's great water solubility makes it an influence medication transporter. Chemical changes resulted in a number of pullulan adjunct with varying solubility. Pullulan has no cell lethality and is a non-immunogenic polymer that can be employed in biomedical implementations. Pullulan degraded faster than dextran in serum. Pullulan's elasticity and thermal steadiness have enabled it to be employed in a variety of applications. Pullulan was derivatized using either DOX or DOX plus folic acid. Periodate oxidation activated pullulan, which was then functionalized through reductive coupling with cysteamine and PEG (NH2)2. DOX-pullulan bio couples has employed for inactive cancer aiming. Pullulan has coupled with many anti tumor medicines to improve their influence.[145]

Pullulan with DOX

DOX is an anti tumor medication that suppresses DNA synthesis in tumor cells. Pullulan's biocompatibility and non-immunogenicity make it suitable as a medication transporter. Pullulan contains a lot of functional collection, which is advantageous in drug transport.[146,147] DOX has harmful influences on usual cells, which is decreased by encapsulating it. Certain studies have shown that encapsulated DOX nanoparticles incorporating folic acid were more effective in tumor suppression compared to free DOX. A pullulan-g-poly (Lactide-co-glycolide) (PLGA) copolymer coupled with folic acid has been developed to deliver DOX to the targeted region within tumor cells. Consequently, pullulan and its various derivatives, including pullulan/PLGA graft copolymers, emerge as promising candidates for drug formulation. The antitumor efficacy of this combination was

demonstrated in KB cancer cells in vitro.[148]

Pullulan with Mitoxantrone

Mitoxantrone is an anti tumor medication that prevents topoisomerase and can interpolate DNA. Because of its lethality, mitoxantrone has restricted use.[149] A derivative of pullulan was employed for loading mitoxantrone. Pullulan nanoparticles that were modified with cholesterol to become aquaphobic were used for this purpose also cholesterol substituted pullulan polymers (CHPs) showed better mitoxantrone transport.[150] The several types of CHPs were synthesized according to the grade of cholesterol replacement and width. The drug release capability of nanoparticles increases with their size. The drug-loaded CHP nanoparticles with the greatest magnitude had greater anti tumor activity in bladder tumor cells, as validated by flow cytometry. The drug-loaded nanoparticles may block the relocation of MB49 cells.[151]

Pullulan with Curcumin

Pullulan is aquaphilic in nature, hence it can transport aquaphilic substances but not aquaphobic compounds.[152] This difficulty could be overcome by acetylating pullulan acetate particles to give them an amphiphilic character. Pullulan acetate could be employed as a transporter for the medicines. To increase curcumin's steadiness and physiochemical characteristics, nanoparticles loaded with pullulan acetate were synthesized. It exhibited superior biocompatibility and hemocompatibility in zebrafish embryos in vitro. The curcumin-pullulan acetate nanoparticle complex acted as a hepatoprotective agent, enhancing the solubility, pH stability, and photostability of curcumin. A galactosylated pullulan-curcumin compound (Figure 8) was developed for targeted curcumin delivery to hepatocarcinoma. Galactosylated pullulan was linked with curcumin via succinic anhydride, introducing acidic functionalities. The galactosylated pullulan-curcumin compound showed increased lethality and internalization rate in HepG2 cells through asialoglycoprotein-mediated endocytosis compared to its non-galactosylated counterpart. These findings suggest that the enhanced uptake of the galactosylated pullulan-curcumin compound may occur via asialoglycoprotein receptor (ASGPR)-mediated endocytosis.

Heparin

Heparin has a wide past of experimental usage as an anticoagulant, comprising research into its use as a transporter to boost the influence of anti tumor medicines. Heparin has been demonstrated to limit tumor cell adhesion, deactivate heparanase, activate NK cell attacks in

the immune organisations, and interfere with the function of development factors such as bFGF and VEGF, hence preventing cancer angiogenesis and metastasis. In this example, less molecular mass heparin proved high efficient than not fractionated heparin. As a result, heparin is commonly employed in anti tumor medication transport organisations. Heparin has lately gained popularity as a drug transporter in macromolecule-anti tumor drug couple models. Although anticoagulant activity is a problem as a drug transporter, this assets of heparin is reduced after drug coupling, lowering the likelihood of haemorrhagic consequences in clinical claims. In research using PTX as a anti tumor pharmacological molecule, it was exposed that anticoagulant movement was abridged with no important impact on hemolysis, however distinct heparin-PTX couples displayed high anti tumor than free PTX. Couples have superior solubility for PTX and have a longer organisation circulation period than free drug solutions of PTX and ATRA. Heparin's unique properties make it a prospective polysaccharide transporter, alongside hyaluronic acid and chitosan.

Heparin with PTX

Heparin-paclitaxel (HP-PTX) and heparin-pyropheophorbide-a (HP-Ppa) were synthesized by conjugating paclitaxel (PTX), a small-molecule chemotherapeutic agent, to heparin using a reactive oxygen species (ROS)-responsive linker, and pyropheophorbide-a (Ppa), a photosensitizer. Nanoparticles containing heparin and PTX are more hazardous. This couple requires linkers, such as carbonate and ethylene diamine, which produce bonds similar to those formed by mide with polymer and ester with medication.

REFERENCES

1. Goodarzi, N. *et al.* ‘A review of polysaccharide anti tumor drug couples for tumor therapy’, *Carbohydrate Polymers*, 2013; 92(2): 1280–1293.
2. Hanahan, D. and Weinberg, R.A. ‘The hallmarks of tumor’, *Cell*, 2000; 100(1): 57–70.
3. Finkel, T., Serrano, M., & Blasco, M. A. The common biology of tumor and ageing. *Nature*, 2007; *448*(7155): 767-774.
4. Chambers, A. F., Groom, A. C., & MacDonald, I. C. Dissemination and development of tumor cells in metastatic sites. *Nature Reviews tumor*, 2002; *2*(8): 563-572.
5. ‘American tumor Society (ACS)’ (2008) *Encyclopedia of Global Health* [Preprint].
6. Skeel, R.T., Ed. Handbook of tumor Chemotherapy, Lippincott Williams and Wilkins: USA, 2007.

7. Singh, Y., Palombo, M., & Sinko, P. J. Recent trends in intended anti tumor prodrug and couple design. *Current medicinal chemistry*, 2008; *15*(18): 1802-1826.
8. Gottesman, M. M., Fojo, T., & Bates, S. E. Multidrug resistance in tumor: role of ATP–dependent transporters. *Nature reviews tumor*, 2002; *2*(1): 48-58.
9. Chabner, B. A., & Roberts Jr, T.G. Chemotherapy and the war on tumor. *Nature Reviews tumor*, 2005; *5*(1): 65-72.
10. Kamb, A., Wee, S., & Lengauer, C. Why is tumor drug discovery so difficult. *Nature reviews Drug discovery*, 2007; *6*(2): 115-120.
11. Muhamad, I. I., Lazim, N. A. M., & Selvakumaran, S. Natural polysaccharide-based composites for drug transport and biomedical applications. In *Natural polysaccharides in drug transport and biomedical applications*, 2019; 419-440.
12. Liu, Z. *et al.* 'Polysaccharides-based nanoparticles as drug transport organisations', *Advanced Drug Transport Reviews*, 2008; 60(15): 1650–1662.
13. Chen, Y., Yao, F., Ming, K., Wang, D., Hu, Y., & Liu, J. Polysaccharides from traditional Chinese medicines: extraction, purification, modification, and biological activity. *Molecules*, 2016; *21*(12): 1705.
14. Ngwuluka, N. C. Responsive polysaccharides and polysaccharides-based nanoparticles for drug transport. In *Stimuli Responsive Polymeric Nanotransporters for Drug Transport Applications*, 2018; *1:* 531-554.
15. Ghadi, R.; Dand, N. BCS class IV drugs: Highly notorious candidates for preparations development. J. Control. Release, 2017; 248: 71–95.
16. Yadav, N., Francis, A. P., Priya, V. V., Patil, S., Mustaq, S., Khan, S. S., ... & Rajagopalan, R. Polysaccharide-drug couples: A tool for enhanced tumor therapy. *Polymers*, 2022; *14*(5): 950.
17. Ravi, P. R., Vats, R., Balija, J., Adapa, S. P. N., & Aditya, N. Modified pullulan nanoparticles for buccal transport of lopinavir: preparations and pharmacokinetic evaluation. *Carbohydrate polymers*, 2014; *110:* 320-328.
18. Park, J. H., Saravanakumar, G., Kim, K., & Kwon, I. C. intended transport of low molecular drugs using chitosan and its adjunct. *Advanced drug transport reviews*, 2010; *62*(1): 28-41.
19. Sood, A., Gupta, A., & Agrawal, G. Recent advances in polysaccharides based biomaterials for drug transport and tissue engineering applications. *Carbohydrate Polymer Technologies and Applications*, 2021; *2:* 100067.

20. Zhang, M., Cui, S. W., Cheung, P. C., & Wang, Q. Antitumor polysaccharides from mushrooms: a review on their isolation process, structural characteristics and antitumor activity. *Trends in Food Science & Technology*, 2007; *18*(1): 4-19.
21. Nauts, H. C., Swift, W. E., & Coley, B. L. The cure of malignant tumors by bacterial toxins as developed by the late William B. Coley, MD, reviewed in the light of modern research, 1946.
22. Luo, Y., & Wang, Q. Recent development of chitosan-based polyelectrolyte complexes with natural polysaccharides for drug transport. *International journal of biological macromolecules*, 2014; *64:* 353-367.
23. Di Martino, A., Sittinger, M., & Risbud, M. V. Chitosan: a versatile biopolymer for orthopaedic tissue-engineering. *Biomaterials*, 2005; *26*(30): 5983-5990.
24. Thein-Han, W. W., Kitiyanant, Y., & Misra, R. D. K. Chitosan as scaffold matrix for tissue engineering. *Materials Science and Technology*, 2008; *24*(9): 1062-1075.
25. Park, J. H., Cho, Y. W., Son, Y. J., Kim, K., Chung, H., Jeong, & Kwon, I. C. Preparation and characterization of self-assembled nanoparticles based on glycol chitosan bearing adriamycin. *Colloid and Polymer Science*, 2006; *284:* 763-770.
26. Prashanth, K. H., & Tharanathan, R. N. Depolymerized products of chitosan as potent inhibitors of tumor-induced angiogenesis. *Biochimica et Biophysica Acta (BBA)-General Subjects*, 2005; *1722*(1): 22-29.
27. Prashanth, K. V. H., & Tharanathan, R. N. Crosslinked chitosan—preparation and characterization. *Carbohydrate research*, 2006; *341*(1): 169-173.
28. Yousefpour, P., Atyabi, F., Vasheghani-Farahani, E., Movahedi, A. A. M., & Dinarvand, R. intended transport of doxorubicin-utilizing chitosan nanoparticles superficial-functionalized with anti-Her2 trastuzumab. *International journal of nanomedicine*, 2011; 1977-1990.
29. Fattahi, A., Golozar, M. A., Varshosaz, J., Sadeghi, H. M., & Fathi, M. Preparation and characterization of micelles of oligomeric chitosan linked to all-trans retinoic acid. *Carbohydrate Polymers*, 2012; *87*(2): 1176-1184.
30. Babu, A., & Ramesh, R. Multifaceted applications of chitosan in tumor drug transport and therapy. *Marine drugs*, 2017; *15*(4): 96.
31. Gavhane, Y. N., Gurav, A. S., & Yadav, A. V. Chitosan and its applications: a review of literature. *Int. J. Res. Pharm. Biomed. Sci.*, 2013; *4*(1): 312-331.
32. Rinaudo, M. Chitin and chitosan: Properties and applications. *Progress in polymer science*, 2006; *31*(7): 603-632.

33. Nahar, K., Hossain, M. K., & Khan, T. A. Alginate and its versatile application in drug transport. *Journal of Pharmaceutical Sciences and Research*, 2017; *9*(5): 606.
34. Lee, M., Nah, J. W., Kwon, Y., Koh, J. J., Ko, K. S., & Kim, S. W. Water-soluble and low molecular mass chitosan-based plasmid DNA transport. *Pharmaceutical research*, 2001; *18:* 427-431.
35. Kumar, S., Dutta, J., & Dutta, P. K. Preparation and characterization of N-heterocyclic chitosan adjunct based gels for biomedical applications. *International Journal of Biological Macromolecules*, 2009; *45*(4): 330-337.
36. Gim, S. *et al.* 'Carbohydrate-based nanomaterials for biomedical applications', *WIREs Nanomedicine and Nanobiotechnology*, 2019; 11(5). doi:10.1002/wnan.1558.
37. Wimardhani, Y. S., Suniarti, D. F., Freisleben, H. J., Wanandi, S. I., Siregar, N. C., & Ikeda, M. A. Chitosan exerts anti tumor activity through induction of apoptosis and cell cycle arrest in buccal tumor cells. *Journal of buccal science*, 2014; *56*(2): 119-126.
38. Park, J. K., Chung, M. J., Choi, H. N., & Park, Y. I. influences of the molecular mass and the degree of deacetylation of chitosan oligosaccharides on antitumor activity. *International journal of molecular sciences*, 2011; *12*(1): 266-277.
39. Adhikari, H. S., & Yadav, P. N. Anti tumor activity of chitosan, chitosan adjunct, and their mechanism of action. *International Journal of Biomaterials*, *2018*.
40. Quiñones, J. P., Peniche, H., & Peniche, C. Chitosan based self-assembled nanoparticles in drug transport. *Polymers*, 2018; *10*(3): 235.
41. Andreadis, C., Vahtsevanos, K., Sidiras, T., Thomaidis, I., Antoniadis, K., & Mouratidou, D. 5-Fluorouracil and cisplatin in the cure of advanced buccal tumor. *Buccal oncology*, 2003; *39*(4): 380-385.
42. Remesh, A. Toxicities of anti tumor drugs and its management. *Int. J. Basic Clin. Pharmacol*, 2012; *1*(2): 2319-2003.
43. Jordan, M. A., & Wilson, L. Microtubules as a aim for anti tumor drugs. *Nature reviews tumor*, 2004; *4*(4): 253-265.
44. Trickler, W. J., Nagvekar, A. A., & Dash, A. K. A novel nanoparticle preparations for sustained paclitaxel transport. *Aaps Pharmscitech*, 2008; *9:* 486-493.
45. Lee, E., Lee, J., Lee, I. H., Yu, M., Kim, H., Chae, S. Y., & Jon, S. Coupled chitosan as a novel platform for buccal transport of paclitaxel. *Journal of medicinal chemistry*, 2008; *51*(20): 6442-6449.
46. Zhao, L., & Zhang, B. Doxorubicin induces cardio lethality through upregulation of death receptors mediated apoptosis in cardiomyocytes. *Scientific reports*, 2017; *7*(1): 44735.

47. Arima, H., Hagiwara, Y., Hirayama, F., & Uekama, K. Enhancement of antitumor influence of doxorubicin by its complexation with γ-cyclodextrin in pegylated liposomes. *Journal of drug aiming*, 2006; *14*(4): 225-232.
48. Park, J. M., Lee, S. Y., Lee, G. H., Chung, E. Y., Chang, K. M., Kwak,& Lee, J. Design and characterisation of doxorubicin-releasing chitosan microspheres for anti tumor chemoembolisation. *Journal of Microencapsulation*, 2012; *29*(7): 695-705.
49. Unsoy, G., Khodadust, R., Yalcin, S., Mutlu, P., & Gunduz, U. Synthesis of Doxorubicin loaded magnetic chitosan nanoparticles for pH responsive intended drug transport. *European Journal of Pharmaceutical Sciences*, 2014; *62:* 243-250.
50. Hwang, H. Y., Kim, I. S., Kwon, I. C., & Kim, Y. H. Tumor aimability and antitumor influence of docetaxel-loaded aquaphobically modified glycol chitosan nanoparticles. *Journal of controlled release*, 2008; *128*(1): 23-31.
51. Jain, A., Thakur, K., Kush, P., & Jain, U. K. Docetaxel loaded chitosan nanoparticles: preparations, characterization and anti tumor studies. *International journal of biological macromolecules*, 2014; *69:* 546-553.
52. P., He, X., Wang, K., Tan, W., He, C., & Zheng, M. A novel methotrexate transport organisations based on chitosan-methotrexate covalently coupled nanoparticles. *Journal of Biomedical Nanotechnology*, 2009; *5*(5): 557-564.
53. Saranya, T. S., Rajan, V. K., Biswas, R., Jayakumar, R., & Sathianarayanan, S. Synthesis, characterisation and biomedical applications of curcumin coupled chitosan microspheres. *International journal of biological macromolecules*, 2018; *110:* 227-233.
54. Ni, J., Tian, F., Dahmani, F. Z., Yang, H., Yue, D., He, S., ... & Yao, J. Curcumin-carboxymethyl chitosan (CNC) couple and CNC/LHR mixed polymeric micelles as new approaches to improve the buccal immersion of P-gp substrate drugs. *Drug transport*, 2016; *23*(9): 3424-3435.
55. Vivek, R., Thangam, R., Nipunbabu, V., Ponraj, T., & Kannan, S. Oxaliplatin-chitosan nanoparticles induced intrinsic apoptotic signaling pathway: a "smart" drug transport organisations to breast tumor cell therapy. *International journal of biological macromolecules*, 2014; *65:* 289-297.M.
56. George, M., & Abraham, T. E. Polyionic hydrocolloids for the intestinal transport of protein drugs: alginate and chitosan—a review. *Journal of controlled release*, 2006; *114*(1): 1-14.
57. Yang, J. S., Xie, Y. J., & He, W. Research progress on chemical modification of alginate: A review. *Carbohydrate polymers*, 2011; *84*(1): 33-39.

58. Rees, D.A. and Welsh, E.J. 'Secondary and tertiary structure of polysaccharides in solutions and Gels', *Angewandte Chemie International Edition in English*, 1977; 16(4): 214–224.
59. Chan, L. W., Lee, H. Y., & Heng, P. W. Mechanisms of external and internal gelation and their impact on the functions of alginate as a coat and transport organisations. *Carbohydrate Polymers*, 2006; *63*(2): 176-187.
60. Torre, M. L., Giunchedi, P., Maggi, L., Stefli, R., Machiste, E. O., & Conte, U. preparations and characterization of calcium alginate beads containing ampicillin. *Pharmaceutical development and technology*, 1998; *3*(2): 193-198.
61. Liu, P., & Krishnan, T. R. Alginate-pectin-poly-L-lysine particulate as a potential controlled release preparations. *Journal of Pharmacy and Pharmacology*, 1999; *51*(2): 141-149.
62. Wong T. W., Chan, L. W., Kho, S. B., & Heng, P. W. S. Design of controlled-release solid dosage forms of alginate and chitosan using microwave. *Journal of Controlled Release*, 2002; *84*(3): 99-114.
63. Ribeiro, A. J., Silva, C., Ferreira, D., & Veiga, F. Chitosan-reinforced alginate microspheres obtained through the emulsification/internal gelation technique. *European journal of pharmaceutical sciences*, 2005; *25*(1): 31-40.
64. Lee, K. Y., & Mooney, D. J. Alginate: properties and biomedical applications. *Progress in polymer science*, 2012; *37*(1): 106-126.
65. Rajaonarivony, M., Vauthier, C., Couarraze, G., Puisieux, F., & Couvreur, P. Development of a new drug transporter made from alginate. *Journal of pharmaceutical sciences*, 1993; *82*(9): 912-917.
66. Lakkakula, J. R., Gujarathi, P., Pansare, P., & Tripathi, S. A comprehensive review on alginate-based transport organisations for the transport of chemotherapeutic agent: Doxorubicin. *Carbohydrate polymers*, 2021; *259:* 117696.
67. Goh, C. H., Heng, P. W. S., & Chan, L. W. Alginates as a useful natural polymer for microencapsulation and therapeutic applications. *Carbohydrate polymers*, 2012; *88*(1): 1-12.
68. Cheng, Y., Yu, S., Wang, J., Qian, H., Wu, W., & Jiang, X. In vitro and in vivo Antitumor Activity of Doxorubicin-Loaded Alginic-Acid-Based Nanoparticles. *Macromolecular bioscience*, 2012; *12*(10): 1326-1335.
69. Tomeh, M. A., Hadianamrei, R., & Zhao, X. A review of curcumin and its adjunct as anti tumor agents. *International journal of molecular sciences*, 2019; *20*(5): 1033.

70. Saralkar, P., & Dash, A. K. Alginate nanoparticles containing curcumin and resveratrol: preparation, characterization, and in vitro evaluation counter to DU145 prostate tumor cell line. *AAPS pharmscitech*, 2017; *18:* 2814-2823.
71. Dey, S., & Sreenivasan, K. Coupling of curcumin onto alginate enhances aqueous solubility and steadiness of curcumin. *Carbohydrate Polymers*, 2014; *99:* 499-507.
72. Dixon, J. M. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast tumor cure. *Expert review of anti tumor therapy*, 2002; *2*(3): 267-275.
73. Jayapal, J. J., & Dhanaraj, S. Exemestane loaded alginate nanoparticles for tumor cure: preparations and in vitro evaluation. *International journal of biological macromolecules*, 2017; 105*:* 416-421.
74. Legha, S. S., Buzdar, A. U., Hortobagyi, G. N., Wiseman, C., Benjamin, R. S., & Blumenschein, G. R. Tamoxifen: use in cure of metastatic breast tumor refractory to combination chemotherapy. *JAMA*, 1979; *242*(1): 49-52.
75. Martínez, A., Benito-Miguel, M., Iglesias, I., Teijón, J. M., & Blanco, M. D. Tamoxifen-loaded thiolated alginate-albumin nanoparticles as antitum buccal drug transport organisations. *Journal of Biomedical Materials Research Part A*, 2012; *100*(6): 1467-1476.
76. Ibrahim, O. M., El-Deeb, N. M., Abbas, H., Elmasry, S. M., & El-Aassar, M. R. Alginate based tamoxifen/metal dual core-folate decorated shell: Nanocomposite intended therapy for breast tumor via ROS-driven NF-κB pathway modulation. *International journal of biological macromolecules*, 2020; *146:* 119-131.
77. Sriamornsak, P. Application of pectin in buccal drug transport. *Expert opinion on drug transport*, 2011; *8*(8): 1009-1023.
78. Yadav, N., Francis, A. P., Priya, V. V., Patil, S., Mustaq, S., Khan, & Rajagopalan, R. Polysaccharide-drug couples: A tool for enhanced tumor therapy. *Polymers*, 2022; *14*(5): 950.
79. Morris, G. A., Kök, S. M., Harding, S. E., & Adams, G. G. Polysaccharide drug transport organisations based on pectin and chitosan. *Biotechnology and genetic engineering reviews*, 2010; *27*(1): 257-284.
80. Ridley, B. L., O'Neill, M. A., & Mohnen, D. Pectins: structure, biosynthesis, and oligogalacturonide-related signaling. *Phytochemistry*, 2001; *57*(6): 929-967.
81. Sinha, V. R., & Kumria, R. Polysaccharides in colon-specific drug transport. *International journal of pharmaceutics*, 2001; *224*(1-2): 19-38.

82. Yang, L., Chu, J. S., & Fix, J. A. Colon-specific drug transport: new approaches and in vitro/in vivo evaluation. *International journal of pharmaceutics*, 2002; *235*(1-2): 1-15.
83. Sriamornsak, P. Application of pectin in buccal drug transport. *Expert opinion on drug transport*, 2011; *8*(8): 1009-1023.
84. Wong, T. W., Colombo, G., & Sonvico, F. Pectin matrix as buccal drug transport vehicle for colon tumor cure. *Aaps PharmSciTech*, 2011; *12:* 201-214.
85. Ghosh, S., Banerjee, S., & Sil, P. C. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update. *Food and Chemical Toxicology*, 2015; *83:* 111-124.
86. Beevers, C. S., & Huang, S. Pharmacological and clinical properties of curcumin. *Botanics: aims and Therapy*, 2011; 5-18.
87. Giordano, A., & Tommonaro, G. Curcumin and tumor. *Nutrients*, 2019; *11*(10): 2376.
88. Shih, F. Y., Su, I. J., Chu, L. L., Lin, X., Kuo, S. C., Hou, Y. C., & Chiang, Y.T. Development of pectin-type B gelatin polyelectrolyte complex for curcumin transport in anti tumor therapy. *International journal of molecular sciences*, 2018; *19*(11): 3625.
89. Mundlia, J., Ahuja, M., Kumar, P., & Pillay, V. Pectin–curcumin composite: Synthesis, molecular modeling and anti tumor. *Polymer Bulletin*, 2019; *76:* 3153-3173.
90. Cheewatanakornkool, K., Niratisai, S., Manchun, S., Dass, C. R., & Sriamornsak, P. Thiolated pectin–doxorubicin couples: Synthesis, characterization and anti tumor activity studies. *Carbohydrate polymers*, 2017; *174:* 493-506.
91. Tao, Y., Zheng, D., Zhao, J., Liu, K., Liu, J., Lei, J., & Wang, L. Self-Assembling pH-Responsive Nanoparticle Platform Based on Pectin–Doxorubicin Couples for Cotransport of Anti tumor Drugs. *ACS omega*, 2021; *6*(15): 9998-10004.
92. Dasari, S., & Tchounwou, P. B. Cisplatin in tumor therapy: molecular mechanisms of action. *European journal of pharmacology*, 2014; *740:* 364-378.
93. Verma, A. K., Chanchal, A., & Chutani, K. Augmentation of anti–tumour activity of cisplatin by pectin nano–couples in B–16 mouse model: pharmacokinetics and in–vivo biodistribution of radio–labelled, aquaphilic nano–couples. *International journal of nanotechnology*, 2012; *9*(10-12): 872-886.
94. Verma, A. K., & Sachin, K. Novel aquaphilic drug polymer nano-couples of cisplatin showing long blood retention profile-its release kinetics, cellular uptake and bio-distribution. *Current drug transport*, 2008; *5*(2): 120-126.
95. Patel, J. J., Karve, M., & Patel, N. K. Guar gum: a versatile material for pharmaceutical industries. *Int J Pharm Pharm Sci.*, 2014; *6*(8): 13-19.

96. Prabaharan, M. Prospective of guar gum and its adjunct as controlled drug transport organisations. *International journal of biological macromolecules*, 2011; *49*(2): 117-124.
97. Pardini, B., Kumar, R., Naccarati, A., Novotny, J., Prasad, R. B., Forsti, & Bermejo, J. L. 5-Fluorouracil-based chemotherapy for colorectal tumor and MTHFR/MTRR genotypes. *British journal of clinical pharmacology*, 2011; *72*(1): 162.
98. Kamal, T., Sarfraz, M., Arafat, M., & Mikov, M. Cross-linked guar gum and sodium borate based microspheres as colon- intended anti tumor drug transport organisations for 5-fluorouracil. *Pakistan Journal of Pharmaceutical Sciences*, 2017; *30*.
99. Lashley, M. R., Niedzinski, E. J., Rogers, J. M., Denison, M. S., & Nantz, M. H. Synthesis and estrogen receptor attraction of a 4-hydroxytamoxifen-labeled ligand for diagnostic imaging. *Bioorganic & medicinal chemistry*, 2002; *10*(12): 4075-4082.
100. Krishnaiah, Y. S. R., Karthikeyan, R. S., & Satyanarayana, V. A three-layer guar gum matrix tablet for buccal controlled transport of highly soluble metoprolol tartrate. *International Journal of Pharmaceutics*, 2002; *241*(2): 353-366.
101. Soppirnath, K. S., & Aminabhavi, T. M. Water transport and drug release study from cross-linked polyacrylamide grafted guar gum hydrogel microspheres for the controlled release application. *European Journal of Pharmaceutics and Biopharmaceutics*, 2002; *53*(1): 87-98.
102. Chaurasia, M., Chourasia, M. K., Jain, N. K., Jain, A., Soni, V., Gupta, Y., & Jain, S. K. Cross-linked guar gum microspheres: A viable approach for improved transport of anti tumor drugs for the cure of colorectal tumor. *Aaps Pharmscitech*, 2006; *7:* E143-E151.
103. Elias, E. J., Anil, S., Ahmad, S., & Daud, A. Colon intended curcumin transport using guar gum. *Natural product communications*, 2010; *5*(6): 1934578X1000500621.
104. Huang, S., & Huang, G. Preparation and drug transport of dextran-drug complex. *Drug transport*, 2019; *26*(1): 252-261.
105. Díaz-Montes, E. Dextran: sources, structures, and properties. *Polysaccharides*, 2021; *2*(3): 554-565.
106. Heinze, T., Liebert, T., Heublein, B., & Hornig, S. Functional polymers based on dextran. *Polysaccharides Ii*, 2006; 199-291.
107. Huang, G., & Huang, H. Application of dextran as nanoscale drug transporters. *Nanomedicine*, 2018; *13*(24): 3149-3158.
108. Zhang, Y., Wang, H., Mukerabigwi, J. F., Liu, M., Luo, S., Lei, & He, H. Self-organized nanoparticle drug transport organisations from a folate- intended dextran–

doxorubicin couple loaded with doxorubicin counter to multidrug resistance. *RSC advances*, 2015; *5*(87): 71164-71173.

109. Cao, D., He, J., Xu, J., Zhang, M., Zhao, L., Duan & Ni, P. Polymeric prodrugs coupled with reduction-sensitive dextran–camptothecin and pH-responsive dextran–doxorubicin: an influence combinatorial drug transport platform for tumor therapy. *Polymer Chemistry*, 2016; *7*(25): 4198-4212.
110. Zhang, X., Zhang, T., Ma, X., Wang, Y., Lu, Y., Jia, & Wen, F. The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug transport organisations for improving chemotherapy influence. *Asian Journal of Pharmaceutical Sciences*, 2020; *15*(5): 605-616.
111. Nakamura, J., Nakajima, N., Matsumura, K., & Hyon, S. H. Water-soluble taxol couples with dextran and aims tumor cells by folic acid immobilization. *Anti tumor research*, 2010; *30*(3): 903-909.
112. Kanwal, S., Naveed, M., Arshad, A., Arshad, A., Firdous, F., Faisal, A., & Yameen, B. Reduction-Sensitive Dextran–Paclitaxel Polymer–Drug Couple: Synthesis, Self-Assembly into Nanoparticles, and In Vitro Anti tumor influence. *Biocouple Chemistry*, 2021; *32*(12): 2516-2529.
113. Georgaki, S., Skopeliti, M., Tsiatas, M., Nicolaou, K. A., Ioannou, K., Husband, A., ... & Tsitsilonis, O.E. Phenoxodiol, an anti tumor isoflavene, induces immunomodulatory influences in vitro and in vivo. *Journal of Cellular and Molecular Medicine*, 2009; *13*(9b): 3929-3938.
114. Gamble, J. R., Xia, P., Hahn, C. N., Drew, J. J., Drogemuller, C. J., Brown, D., & Vadas, M.A. Phenoxodiol, an experimental anti tumor drug, shows potent antiangiogenic properties in addition to its antitumour influences. *International journal of tumor*, 2006; *118*(10): 2412-2420.
115. Yee, E. M., Cirillo, G., Brandl, M. B., Black, D. S., Vittorio, O., & Kumar, N. Synthesis of dextran–phenoxodiol and evaluation of its physical steadiness and biological activity. *Frontiers in Bioengineering and Biotechnology*, 2019; *7:* 183.
116. Nevozhay, D., Budzynska, R., Jagiello, M., Kanska, U., Omar, M. S., Opolski, A., ... & Boratynski, J. The influence of the substitution level of some dextran-methotrexate couples on their antitumor activity in experimental tumor models. *Anti tumor research*, 2006; *26*(3A): 2179-2186.

117. Dang, W., Colvin, O. M., Brem, H., & Saltzman, W. M. Covalent coupling of methotrexate to dextran enhances the penetration of anti tumor into a tissue-like matrix. *tumor research*, 1994; *54*(7): 1729-1735.
118. Huang, Q., Zhang, L., Sun, X., Zeng, K., Li, J., & Liu, Y. N. Coating of carboxymethyl dextran on liposomal curcumin to improve the anti tumor activity. *RSC advances*, 2014; *4*(103): 59211-59217.
119. Raveendran, R., Bhuvaneshwar, G. S., & Sharma, C. P. Hemocompatible curcumin–dextran micelles as pH sensitive pro-drugs for enhanced therapeutic influence in tumor cells. *Carbohydrate polymers*, 2016; *137:* 497-507.
120. Zare, M., Norouzi Sarkati, M., Tashakkorian, H., Partovi, R., & Rahaiee, S. Dextran-immobilized curcumin: An efficient agent counter to food pathogens and tumor cells. *Journal of Bioactive and Compatible Polymers*, 2019; *34*(4-5): 309-320.
121. Curcio, M., Cirillo, G., Tucci, P., Farfalla, A., Bevacqua, E., Vittorio, & Nicoletta, F. P. Dextran-curcumin nanoparticles as a methotrexate transport vehicle: A step forward in breast tumor combination therapy. *Pharmaceuticals*, 2019; *13*(1): 2.
122. Prestwich, G.D. 'Hyaluronic acid-based clinical biomaterials derived for cell and molecule transport in Regenerative Medicine', *Journal of Controlled Release*, 2011a; 155(2): 193–199.
123. Xu, X., Jha, A. K., Harrington, D. A., Farach-Carson, M. C., & Jia, X. Hyaluronic acid-based hydrogels: from a natural polysaccharide to complex networks. *Soft matter*, 2012; *8*(12): 3280-3294.
124. Weaver, B. A. How Taxol/paclitaxel kills tumor cells. *Molecular biology of the cell*, 2014; *25*(18): 2677-2681.
125. Lee, H., Lee, K., & Park, T. G. Hyaluronic acid− paclitaxel couple micelles: Synthesis, characterization, and antitumor activity. *Biocouple chemistry*, 2008; *19*(6): 1319-1325.
126. Wickens, J. M., Alsaab, H. O., Kesharwani, P., Bhise, K., Amin, M. C. I. M., Tekade, & Iyer, A. K. Recent advances in hyaluronic acid-decorated nanotransporters for intended tumor therapy. *Drug discovery today*, 2017; *22*(4): 665-680.
127. Li, J., Huang, P., Chang, L., Long, X., Dong, A., Liu, J., ... & Deng, L. Tumor aiming and pH-responsive polyelectrolyte complex nanoparticles based on hyaluronic acid-paclitaxel couples and Chitosan for buccal transport of paclitaxel. *Macromolecular Research*, 2013; *21:* 1331-1337.

128. Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. Doxorubicin pathways: pharmacodynamics and adverse influences. *Pharmacogenetics and genomics*, 2011; *21*(7): 440-446.
129. Cai, S., Thati, S., Bagby, T. R., Diab, H. M., Davies, N. M., Cohen, M. S., & Forrest, M.L. Localized doxorubicin chemotherapy with a biopolymeric nanotransporter improves survival and reduces lethality in xenografts of human breast tumor. *Journal of Controlled Release*, 2010; *146*(2): 212-218.
130. Florea, A. M., & Büsselberg, D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side influences. *tumors*, 2011; *3*(1): 1351-1371.
131. Venditto, V. J., & Simanek, E. E. Tumor therapies utilizing the camptothecins: a review of the in vivo literature. *Molecular pharmaceutics*, 2010; *7*(2): 307-349.
132. Pizzolato, J. F., & Saltz, L. B. The camptothecins. *The Lancet*, 2003; *361*(9376): 2235-2242.
133. Serafino, A., Zonfrillo, M., Andreola, F., Psaila, R., Mercuri, L., Moroni, & Pierimarchi, P. CD44- aiming for antitumor drug transport: a new SN-38-hyaluronan biocouple for locoregional cure of peritoneal carcinomatosis. *Current tumor Drug aims*, 2011; *11*(5): 572-585.
134. Montagner, I. M., Merlo, A., Zuccolotto, G., Renier, D., Campisi, M., Pasut, & Rosato, A. (2014). Peritoneal tumor carcinomatosis: pharmacological aiming with hyaluronan-based biocouples overcomes therapeutic indications of current drugs. *PloS one*, *9*(11): e112240.
135. Di, L. and Kerns, E.H. 'preparations', *Drug-Like Properties*, 2016; 497–510.
136. Sharma, N., & Baldi, A. Exploring versatile applications of cyclodextrins: an overview. *Drug transport*, 2016; *23*(3): 729-747.
137. Çırpanlı, Y.; Allard, E.; Passirani, C.; Bilensoy, E.; Lemaire, L.; Çalı¸s, S.; Benoit, J.-P. Antitum buccal activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int. J. Pharm., 2011; 403: 201–206.
138. Çirpanli, Y., Bilensoy, E., Doğan, A. L., & Çaliş, S. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for influence camptothecin transport. *European Journal of Pharmaceutics and Biopharmaceutics*, 2009; *73*(1): 82-89.
139. Ghalandarlaki, N., Alizadeh, A. M., & Ashkani-Esfahani, S. Nanotechnology-applied curcumin for different diseases therapy. *BioMed research international*, *2014*.

140. Zhang, L., Man, S., Qiu, H., Liu, Z., Zhang, M., Ma, L., & Gao, W. Curcumin-cyclodextrin complexes enhanced the anti tumor influences of curcumin. *Environmental Toxicology and Pharmacology*, 2016; *48:* 31-38.
141. Jing, J., Szarpak-Jankowska, A., Guillot, R., Pignot-Paintrand, I., Picart, C., & Auzély-Velty, R. Cyclodextrin/paclitaxel complex in biodegradable capsules for breast tumor cure. *Chemistry of Materials*, 2013; *25*(19): 3867-3873.
142. Yu, S., Zhang, Y., Wang, X., Zhen, X., Zhang, Z., Wu, W., & Jiang, X. Synthesis of paclitaxel-coupled β-cyclodextrin polyrotaxane and its antitumor activity. *Angewandte Chemie International Edition*, 2013; *52*(28).
143. Yusheng, S., Chenjun, M., Yingying, H., Tiantian, W., & Liefeng, Z. Multifunctional nanoparticles of paclitaxel and cyclodextrin–polypeptide couples with in vitro anti tumor activity. *Pharmaceutical Development and Technology*, 2020; *25*(9): 1071-1080.
144. Bishwambhar Mishra, B. M., Vuppu Suneetha, V. S., & Ramalingam, C. (2011). An overview of mechanistic characterization and optimization of pullulan producing microorganism.
145. Mishra, B., Vuppu, S., & Rath, K. The role of microbial pullulan, a biopolymer in pharmaceutical approaches: A review. *Journal of Applied Pharmaceutical Science*, 2011; 45-50.
146. Jeans, A. Dextrans and pullulans: Industrially significant α-d-glucans. *Encyclopedia of Polymer Science and Technology*, 1966; *4:* 819-821.
147. Yuen, S. Pullulan and Its Applications. Process Biochem, 1974; 22: 7–9.
148. Gao, F., Li, L., Liu, T., Hao, N., Liu, H., Tan, L., ... & Tang, F. Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor influences. *Nanoscale*, 2012; *4*(11): 3365-3372.
149. Posner, L. E., Dukart, G., Goldberg, J., Bernstein, T., & Cartwright, K. Mitoxantrone: an overview of safety and lethality. *Investigational New Drugs*, 1985; *3:* 123-132.
150. Tao, X., Tao, T., Wen, Y., Yi, J., He, L., Huang, Z., ... & Yang, X. Novel transport of mitoxantrone with aquaphobically modified pullulan nanoparticles to inhibit bladder tumor cell and the influence of nano-drug size on inhibition effectiveness. *Nanoscale research letters*, 2018; *13:* 1-12.
151. Falvo, E., Malagrinò, F., Arcovito, A., Fazi, F., Colotti, G., Tremante, E., ... & Ceci, P. The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity. *Journal of controlled release*, 2018; *275:* 177-185.

152. Singh, R. S., Kaur, N., & Kennedy, J. F. Pullulan and pullulan adjunct as promising biomolecules for drug and gene aiming. *Carbohydrate Polymers*, 2015; *123:* 190-207.
153. Ganeshkumar, M., Ponrasu, T., Subamekala, M. K., Janani, M., & Suguna, L. Curcumin loaded on pullulan acetate nanoparticles protects the liver from damage induced by DEN. *RSC advances*, 2016; *6*(7): 5599-5610.
154. Sarika, P. R., James, N. R., Nishna, N., Kumar, P. A., & Raj, D. K. Galactosylated pullulan–curcumin couple micelles for site specific anti tumor activity to hepatocarcinoma cells. *Colloids and superficials B: Biointerfaces*, 2015; *133:* 347-355.